Effect of Atorvastatin on Carotid Intima Media Thickness

NCT ID: NCT04306627

Last Updated: 2020-03-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-15
• Study Completion Date: 2021-02-28

Brief Summary

The investigators hypothesize that additive effects of combined antihypertensive medications and statin in a single pill combination may better reduce progression of vascular remodeling and inhibit atherosclerosis progression. The fixed association of atorvastatin, perindopril and amlodipine under the name of Lipertance is the first fixed combination of these three groups to control the risk factors that are hypertension and dyslipidemia which can be used both in primary and secondary cardiovascular prevention .

Detailed Description

Eligible participants with appropriately signed informed consent will be randomized to either the perindopril+amlodipin or perindopril+amlodipin+atorvastatin combinations.

Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.

Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia.

Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . The investigators will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol. Liver enzyme markers will be assessed in patients on additional statin treatment on day 90 for safety assessment. All participants will be followed-up for 6 months.

Inclusion criteria

• Patients aged between 45 and 85 years
• blood pressure ≥ 140/90 mmHg with one antihypertensive drug or 150/100 mHg for untreated patients
• plasma LDL-cholesterol concentrations > 2,5mm/L (without concomitant hypolipidemic drugs)
• at least one additional cardiovascular risk factor apart of arterial hypertension
• minimal thickness of intima media complex at least 0,8 mm.

Exclusion criteria

• premenopausal females with potential for pregnancy
• angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker therapy in the previous 3 months,
• initiation or change in dose of statin therapy within previous 3 months
• anticipated change in lipid lowering therapy
• acute coronary or cerebrovascular event within 2 months
• glomerular filtration rate < 30 ml/min
• previous history of side effects to RAAS inhibitors and Ca channel blocking agents
• inability to give informed consent
• inability to undergo carotid ultrasound examination.

Adverse events (AE)

Based on the intention-to-treat the patient population, safety will be checked by recording adverse effects throughout the study: severe AEs regardless as to whether or not there is causal relationship between the AEs and the study; and relevant AEs such as myalgia, cough , palpitations, peripheric edemas, diziness symptoms. When the investigators confirm these AEs, the grade of severity, procedures, outcomes, and relationship to the study drug will be assessed and recorded.

Serious adverse event (SAE)

A serious adverse event is an AE occurring during any study phase and at any dose of the investigational product that fulfills one or more of the following criteria: results in death, is immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is an important medical event that may jeopardize the subject or may require medical intervention to prevent one of the outcomes listed above.

The Investigator must inform the Sponsor of any SAE that occurs in the course of the study within 48 hours of when he or she becomes aware of it.

Carotid Ultrasound An ultrasound linear probe with 5-10 MHz linear transducer will be used for measuring the carotid artery intima media thickness ( IMT ). The carotid artery will be scanned by 3 trained in vascular ultrasound and echocardiography physicians. All study subjects will be examined in the supine position with the head tilted backward. Measurements of the left and right IMT of the posterior wall of the common carotid, 1 cm distal to the bulb bifurcation, by ultrasound 2D exam will be performed

Blood pressure (BP) will be measured at the University Cardiology Clinic by a trained nurse or physician using a calibrated and validated digital sphygmomanometer. BP measurements will be taken with the patient in a seated position with the arm supported at heart level, after a 5 min rest and after abstaining from food, beverages containing caffeine, and smoking for at least 2 h prior to BP measurement. BP will be recorded as three serial measurements at intervals of 30 sec on both arms.

Conditions

Essential Hypertension; Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Perindopril/Amlodipine arm

Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.

Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia.

Group Type: ACTIVE_COMPARATOR

Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment

Intervention Type: DRUG

comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups

Perindopril/Amlodipine/Atorvastatin arm

Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.

Group Type: ACTIVE_COMPARATOR

Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment

Intervention Type: DRUG

comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups

Interventions

Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment

comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• • Patients aged between 45 and 85 years

• blood pressure ≥ 140/90 mmHg with one antihypertensive drug or 150/100 mHg for untreated patients
• plasma LDL-cholesterol concentrations > 4.1 mmol/L without hypolipidemic drugs within the last 6 months
• at least one additional cardiovascular risk factor apart of arterial hypertension
• minimal thickness of intima media complex at least 0,8 mm.

Exclusion Criteria

• premenopausal females with potential for pregnancy
• angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker therapy in the previous 3 months,
• initiation or change in dose of statin therapy within previous 3 months
• anticipated change in lipid lowering therapy
• acute coronary or cerebrovascular event within 2 months
• glomerular filtration rate < 30 ml/min
• previous history of side effects to RAAS inhibitors and Ca channel blocking agents
• inability to give informed consent
• inability to undergo carotid ultrasound examination

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Servier

INDUSTRY

Sponsor Role: collaborator

Yerevan State Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hamayak Sisakian, MD

Role: PRINCIPAL_INVESTIGATOR

Yerevan State Medical University

Central Contacts

Hamayak S Sisakian, MD

Role: CONTACT

hamayak.sisakian@doctor.com

+37410582023

Other Identifiers

YerevanStateMU

Identifier Type: -

Identifier Source: org_study_id